UK approves Lilly’s Alzheimer’s drug but labels it ‘too expensive’ for NHS use
The UK has approved Eli Lilly's new Alzheimer’s treatment, donanemab, which has shown promise in slowing cognitive decline. However, the National Institute for Health and ... Read More
Lupin gets UK NICE recommendation for Namuscla in NDM
Lupin said that the UK’ National Institute for Health and Care Excellence (NICE) has recommended Namuscla (mexiletine), an antimyotonic agent, for the approval of its ... Read More